Exploring Vascular Access Devices in Cancer Care: A Scoping Review

Introduction

As the global incidence of cancer continues to rise, the need for effective intravenous therapy and diagnostics in cancer patients becomes increasingly significant. Vascular access devices (VADs) play a crucial role in delivering systemic anti-cancer therapy (SACT), but the choice of VAD type and its impact on patient outcomes remain areas of exploration.

Objective

Our objective was to conduct a comprehensive scoping review to understand the landscape of VAD usage in delivering SACT to cancer patients. We aimed to identify the types of VADs used, insertion and post-insertion complications, geographical variations, clinical environments, and potential impacts on quality of life (QOL).

Methods

Utilizing JBI scoping review methodology, we searched for articles published in English between 2012 and 2022. After screening, 240 articles met our inclusion criteria, covering various study designs and geographical locations.

Key Findings

Our review identified a wide range of VAD types used for SACT delivery, with tunnelled intravenous VADs being particularly prevalent. Catheter-related thrombosis and infections were the most common complications reported. Interestingly, the majority of publications originated from China, indicating regional variations in VAD practices. However, we noted a lack of core outcome sets specific to VADs for SACT and limited data on QOL aspects related to VAD usage.

Implications

The findings underscore the need for further research, including systematic reviews, meta-analyses, and the development of core outcome sets for SACT via VADs. High-quality research programs and initiatives led by comprehensive cancer centers are essential to drive advancements in VAD usage and improve patient outcomes.

Conclusion

This scoping review sheds light on the current landscape of VAD usage in delivering SACT to cancer patients. Moving forward, prioritizing research funding and collaborative efforts can enhance our understanding and optimize the use of VADs in cancer care.

Read More:https://pubmed.ncbi.nlm.nih.gov/38492760/ 

Authors: C Duggan, O Hernon, R Dunne, V McInerney, S R Walsh, A Lowery, M McCarthy, P J Carr